Caricamento...
Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease
Treatment of inflammatory bowel disease has significantly improved since the introduction of biological agents, such as infliximab, adalimumab, certolizumab pegol, and golimumab. The Food and Drug Administration has classified these factors in category B, which means that they do not demonstrate a f...
Salvato in:
| Pubblicato in: | World J Gastroenterol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Baishideng Publishing Group Inc
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4679752/ https://ncbi.nlm.nih.gov/pubmed/26715803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i47.13205 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|